Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
APEN Apollo Endosurgery 06:56 11/09/18 11/09 06:56 11/09/18 06:56 Downgrade	Apollo Endosurgery rating change at Northland » Apollo Endosurgery… Apollo Endosurgery downgraded to Underperform from Market Perform at Northland. Northland analyst Suraj Kalia downgraded Apollo Endosurgery to Underperform from Market Perform citing the shifting focus to OverStitch, a lower margin product, continued softness in Orbera and the declining LAP-BAND business. The ongoing softness in LAP-BAND, combined with the deceleration in Orbera, has the analyst worried and "nothing in company commentary [...] lent comfort in the business trajectory reversing anytime soon," Kalia tells investors. The price target on Apollo Endosurgery shares was lowered to $3 from $7. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Nov 27 Nov

Over a week ago
APEN Apollo Endosurgery $5.81 -0.29 (-4.75%) 16:01 11/08/18 11/08 16:01 11/08/18 16:01 Earnings	Apollo Endosurgery reports Q3 EPS (45c), consnesus (35c) » Reports Q3 revenue… Reports Q3 revenue $14.14M, consensus $16.22M. Todd Newton, CEO of Apollo, commented, "ESS sales contributed 37% of overall revenue in the third quarter, showing solid progress despite a challenging comparable period in certain OUS markets in the prior year. We also achieved good IGB sales growth in the markets where Orbera365, our 12-month product is available. And finally, we are pleased to announce the completion of our two gross margin improvement projects that will add an estimated $2 million annually to our Endo gross margin beginning in 2019." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Nov 15 Nov 27 Nov

Over a month ago
APEN Apollo Endosurgery $6.99 -0.11 (-1.55%) 08:15 10/09/18 10/09 08:15 10/09/18 08:15 Hot Stocks	Apollo Endosurgery, Slater Endoscopy announce distribution agreement » Apollo Endosurgery… Apollo Endosurgery announced that it has entered into an agreement with Slater Endoscopy to distribute the cold Ensizor Flexible Endoscopic Scissors in the United States, Europe, and select other markets. The Ensizor Flexible Endoscopic Scissor is indicated to cut and dissect tissue and sutures during endoscopic procedures. The innovative Edge Flex technology greatly enhances the cutting performance of endoscopic scissors by offering a very thin, yet rigid blade construction. The rigid armature provides unparalleled strength while the flexible blades ensure constant cutting contact providing physicians reliable and consistent cutting performance. The Ensizor Flexible Endoscopic Scissors are available for sale immediately through Apollo in the United States and select European countries. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Nov
APEN Apollo Endosurgery $7.17 0.04 (0.56%) 08:06 10/01/18 10/01 08:06 10/01/18 08:06 Hot Stocks	Apollo Endosurgery completes enrollment for ORBERA study » Apollo Endosurgery… Apollo Endosurgery announced completion of enrollment in the ORBERA Post Approval Study evaluating the ORBERA intragastric balloon. The ORBERA Post Approval Study is a multi-center, open-label, prospective study of the safety and efficacy of the ORBERA system within the US. The study was a requirement of the US FDA's approval of ORBERA in August of 2015. The study has enrolled 281 patients across 11 centers. The endpoints include the patient's percentage of total body weight loss at 26 weeks and 12 months after balloon placement and the rate of adverse events at 26 weeks, the indwell time allowed for the balloon. This study includes 12 months of follow-up after balloon placement: six months with the balloon and an additional six months of follow-up after the balloon's removal. Patient follow up and final study results are expected in early 2020. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Nov

Over a quarter ago
APEN Apollo Endosurgery $8.36 (0.00%) 09:40 08/09/18 08/09 09:40 08/09/18 09:40 Downgrade	Apollo Endosurgery rating change » Apollo Endosurgery… Apollo Endosurgery downgraded to Market Perform following Q2 results at Northland. As previously reported, Northland analyst Suraj Kalia downgraded Apollo Endosurgery to Market Perform from Outperform following quarterly results, citing the shifting focus on OverStitch, a lower margin product, continued softness in Orbera and declining LAP-BAND business. The analyst notes that strong performance on OverStitch was offset by weak Orbera and LAP-BAND numbers. Kalia also lowered his price target on the shares to $7 from $12. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

APEN Apollo Endosurgery $8.36 0.09 (1.09%) 08:01 08/09/18 08/09 08:01 08/09/18 08:01 Downgrade	Apollo Endosurgery rating change at Northland » Apollo Endosurgery… Apollo Endosurgery downgraded to Market Perform from Outperform at Northland 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
APEN Apollo Endosurgery $8.36 0.09 (1.09%) 16:12 08/08/18 08/08 16:12 08/08/18 16:12 Earnings	Apollo Endosurgery reports Q2 EPS (53c), consensus (44c) » Reports Q2 revenue… Reports Q2 revenue $15.8M, consensus $16.64M. The company said, "During the second quarter, we made progress on a number of fronts. OverStitch sales were up 37% compared to the second quarter of 2017, becoming our top selling product in direct markets, while we also saw strong growth in sales of Orbera365 in the markets in which it is available. At the beginning of June, we received FDA approval for updated U.S. Orbera labeling to reflect the product's most current safety information to both physicians and patients. We continued to move closer to the introduction of OverStitch Sx and made progress both on our margin improvement projects and our clinical data initiatives." Cash, cash equivalents and restricted cash were $35.4M as of June 30. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Aug
APEN Apollo Endosurgery $8.37 -0.63 (-7.00%) 08:38 07/17/18 07/17 08:38 07/17/18 08:38 Downgrade	Apollo Endosurgery rating change at Roth Capital » Apollo Endosurgery… Apollo Endosurgery downgraded to Neutral from Buy at Roth Capital. Roth Capital analyst David Solomon downgraded Apollo Endosurgery to Neutral from Buy, with a $8.75 price target, after assuming coverage of the name. Despite the strengthened balance sheet and near-term Sx launch, the analyst believes that recent share-price increases reflect these positives. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
APEN Apollo Endosurgery $6.81 0.05 (0.74%) 08:43 06/29/18 06/29 08:43 06/29/18 08:43 Recommendations	Apollo Endosurgery analyst commentary at Craig-Hallum » Craig-Hallum focused on… Craig-Hallum focused on upside potential OverStitch provides for Apollo. After Apollo Endosurgery announced that it has received a special 510(k) clearance from the FDA related to an accessory for its OverStitch Sx endoscopic suturing system, Craig-Hallum analyst Matt Hewitt reiterated a Buy rating and $11 price target on the stock, telling investors in a research note that he believes accessory will improve the "already impressive" safety profile of the device. Hewitt says there are many reasons to be bullish on the potential for OverStitch, including the size of the obesity market worldwide, the fact that current treatments for obesity are either short-term fixes or anatomy altering procedures, and previous clinical data that strongly suggests the MERIT trial will be a success. He says he is increasingly focused on the "significant" upside potential that OverStitch provides for Apollo. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
APEN Apollo Endosurgery $6.81 0.05 (0.74%) 16:02 06/28/18 06/28 16:02 06/28/18 16:02 Hot Stocks	Apollo Endosurgery receives special FDA clearance for Overstitch Sx system » Apollo Endosurgery… Apollo Endosurgery announced that it has received Special 510(k) clearance from the U.S. Food and Drug Administration for OverStitch Sx Endoscopic Suturing System. The OverStitch Sx System, a new, full-thickness flexible endoscopic suturing system, received initial 510(k) clearance in November 2017. The Special 510(k) addressed an accessory to the system that is intended to ease the attachment of the device to compatible endoscopes (single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm). The Special 510(k) clearance is the last regulatory requirement needed prior to the system's introduction into the US market. Flexible endoscopic suturing using Apollo's current version of OverStitch is an important tool for both surgeons and gastroenterologists, but it is currently only compatible with a limited number of dual-channel endoscopes and physicians without access to this specific capital equipment cannot leverage the benefits of endoscopic suturing. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

On The Fly

News and insights, exclusive to thefly.com

07:32	U.S. stocks pointed to higher open despite UK's Brexit chaos»
20:25	Notable companies reporting before tomorrow's open»
18:54	Fly Intel: After Hours Movers»
15:12	Neurocrine slides as Ingrezza serious cases count updated in FDA system»
13:02	Notable companies reporting before tomorrow's open»

View all On The Fly Stories »

Upcoming
Events (10)

AINC ...	Southwest Ideas Conference
	Global Energy Conference
LBTYA ...	European Tech, Media & Telecom Conference
VCYT ...	Medical Technologies & Diagnostics Forum
	Macro Economic Outlook Conference
AVHI ...	5th Annual Housing Conference
	Japan Corporate Day
EADSY	Next.2018
	21st India Forum
	West Coast Internet Bus Tour

View all of today’s events »

Today’s
Syndicate (9)

BCSF	IPO
CNTX	IPO
WEI	IPO
ED	Secondary
NGHC	Secondary
VICI	Secondary
AGNC	Spot Secondary
HSDT	Spot Secondary
KREF	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial